

Parambir Dulai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6947816/publications.pdf>

Version: 2024-02-01

175
papers

8,223
citations

61945

43
h-index

56687

83
g-index

182
all docs

182
docs citations

182
times ranked

9336
citing authors

#	ARTICLE	IF	CITATIONS
1	A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 555-562.	0.9	3
2	The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 716-725.	0.9	5
3	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
4	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	2.4	6
5	Comparative Risk of Serious Infections With Tumor Necrosis Factor Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e74-e88.	2.4	18
6	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <i>Gut</i> , 2022, 71, 1078-1087.	6.1	18
7	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	2.4	22
8	Clinical Decision Support Tool for Infliximab in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1192-e1195.	2.4	1
9	Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naïve Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1588-1597.e3.	2.4	12
10	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1095-1104.e9.	2.4	21
11	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	0.6	9
12	Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 398-413.	0.6	11
13	Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 616-624.	0.6	2
14	Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2728-2740.e1.	2.4	15
15	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 447-454.e1.	2.4	4
16	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
17	Multi-omics analyses of the ulcerative colitis gut microbiome link <i>Bacteroides vulgatus</i> proteases with disease severity. <i>Nature Microbiology</i> , 2022, 7, 262-276.	5.9	110
18	Categorising Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1011-1019.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1151-1159.	1.9	4
20	Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1040-1041.	1.9	1
21	Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00484.	1.3	8
22	Digital Therapeutics Care Utilizing Genetic and Gut Microbiome Signals for the Management of Functional Gastrointestinal Disorders: Results From a Preliminary Retrospective Study. <i>Frontiers in Microbiology</i> , 2022, 13, 826916.	1.5	9
23	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 35-53.	2.3	10
24	A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. <i>BioDrugs</i> , 2022, 36, 85-93.	2.2	2
25	Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 191-200.	1.9	34
26	Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1555-1564.	0.9	5
27	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
28	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 1106-1117.	0.2	28
29	Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2022, .	1.0	0
30	National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1068-1078.	0.9	12
31	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	2.4	121
32	Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2564-2569.	1.1	10
33	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 511-518.e6.	2.4	28
34	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1209-1217.e2.	2.4	12
35	Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1288-1291.	2.4	11
36	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 639-646.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 195-202.	0.6	10
38	High pooled performance of convolutional neural networks in computer-aided diagnosis of GI ulcers and/or hemorrhage on wireless capsule endoscopy images: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 356-364.e4.	0.5	30
39	Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 603-616.	0.9	25
40	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 462-470.	0.6	16
41	Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 567-574.	0.6	14
42	Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1610-1619.	0.9	16
43	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1649-1657.	0.6	10
44	Risks of undertreating and overtreating disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 29-29.	1.4	0
45	The current state of comparative effectiveness research in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 16-17.	1.4	0
46	A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 1709-1719.	0.2	4
47	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
48	Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1170-1179.e10.	2.4	5
49	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 482-497.	3.7	28
50	Effectiveness of recombinant zoster vaccine (RZV) in patients with inflammatory bowel disease. <i>Vaccine</i> , 2021, 39, 4199-4202.	1.7	11
51	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
52	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1114-1119.	0.6	9
53	Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1277-1284.	0.9	7
54	Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1215-1223.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record Database. <i>Pancreas</i> , 2021, 50, 1212-1217.	0.5	2
56	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitisâ€”authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 957-958.	1.9	0
57	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	2.4	22
58	Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 69-81.e3.	2.4	137
59	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderateâ€”Severe Ulcerative Colitis and Crohnâ€™s Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 515-523.	0.9	14
60	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohnâ€™s Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
61	Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1939-1948.e7.	2.4	22
62	First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2179-2191.e6.	2.4	222
63	How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1300-1308.	2.4	19
64	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 424-431.e7.	2.4	15
65	Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1429-1435.	0.9	8
66	Prevalence of endoscopic improvement and remission according to patientâ€™reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	1.9	26
67	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30
68	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 15-32.	0.3	3
69	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	1.9	48
70	A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3740-3752.	1.1	1
71	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohnâ€™s disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	1.4	7
72	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.2	23

#	ARTICLE	IF	CITATIONS
73	Sensitivity analysis of treatment effect to unmeasured confounding in observational studies with survival and competing risks outcomes. <i>Statistics in Medicine</i> , 2020, 39, 3397-3411.	0.8	17
74	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 568-569.	1.9	0
75	A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 955-963.	1.9	15
76	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	1.9	27
77	Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. <i>Science Immunology</i> , 2020, 5, .	5.6	127
78	Accuracy of convolutional neural network-based artificial intelligence in diagnosis of gastrointestinal lesions based on endoscopic images: A systematic review and meta-analysis. <i>Endoscopy International Open</i> , 2020, 08, E1584-E1594.	0.9	12
79	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 1262-1275.e7.	0.6	101
80	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
81	Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era—getting nearer? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 738-739.	1.9	4
82	Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2437-2447.e6.	2.4	39
83	Predicting Response to Vedolizumab in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 76.	1.2	11
84	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 481-491.	1.9	10
85	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
86	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 393-405.	3.7	78
87	Host engulfment pathway controls inflammation in inflammatory bowel disease. <i>FEBS Journal</i> , 2020, 287, 3967-3988.	2.2	40
88	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1364-1377.	0.6	7
89	Risk of de novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1067-1075.	1.9	10
90	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1031-1038.	1.9	80

#	ARTICLE	IF	CITATIONS
91	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	1.9	33
92	Using Artificial Intelligence to Identify Patients With Ulcerative Colitis in Endoscopic and Histologic Remission. <i>Gastroenterology</i> , 2020, 158, 2045-2047.	0.6	9
93	Convolutional neural networks in the computer-aided diagnosis of Helicobacter pylori infection and non-causal comparison to physician endoscopists: a systematic review with meta-analysis. <i>Annals of Gastroenterology</i> , 2020, 34, 20-25.	0.4	11
94	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	4
95	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	1.9	5
96	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	4.9	51
97	Sa1814 " Early Combined Immunosuppression is More Effective for Reducing Crohn's Disease Related Complications in Isolated Colonic Than Ileal Dominant Crohn's: Post-Hoc Analysis of React Trial. <i>Gastroenterology</i> , 2019, 156, S-412.	0.6	1
98	Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 848-857.	1.9	40
99	Mo1801 " Incorporating Fecal Calprotectin in Clinical Practice in Patients with Ulcerative Colitis: A Grade-Based Approach. <i>Gastroenterology</i> , 2019, 156, S-843.	0.6	3
100	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 157, 1032-1043.e1.	0.6	48
101	In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101619.	1.0	4
102	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1201-1216.	0.6	25
103	334 " Development and Validation of a Clinical Scoring Tool for Predicting Treatment Outcomes with Vedolizumab in Patients with Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, S-67.	0.6	1
104	Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2634-2643.	2.4	85
105	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
106	US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1828-1837.	0.9	34
107	A product review of vedolizumab in inflammatory bowel disease. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2482-2490.	1.4	20
108	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	1.9	24

#	ARTICLE	IF	CITATIONS
109	Serum Concentrations of 7 α -hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2722-2730.e4.	2.4	26
110	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1646-1647.	2.4	1
111	Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2478-2488.	1.1	9
112	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
113	637â€fClinical Prediction Model and Decision Support Tool for Ustekinumab in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S373-S373.	0.2	13
114	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.2	42
115	688â€fProbability of Vedolizumab Response as Defined by Clinical Decision Support Tool Is Associated With Lower Risk of Serious Infection in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S403-S404.	0.2	2
116	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 270-282.	0.9	48
117	Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 395-396.	2.4	2
118	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
119	Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2019, 64, 382-390.	1.1	22
120	Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 172-181.	0.6	27
121	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 410-420.	0.9	28
122	Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 871-876.	0.9	52
123	Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1316-1320.	0.9	18
124	High body mass index is associated with increased risk of treatment failure and surgery in biologicâ€treated patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1472-1479.	1.9	63
125	Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 1516-1523.	0.2	47
126	Acute severe ulcerative colitis: latest evidence and therapeutic implications. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 65-72.	1.1	50

#	ARTICLE	IF	CITATIONS
127	Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e132.	1.3	97
128	OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn's disease: a multicentre consortium propensity score-matched analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S018-S018.	0.6	7
129	Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 343-356.e3.	2.4	299
130	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 167-177.	0.6	44
131	Population Health Management for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 37-45.	0.6	58
132	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
133	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018, 113, 1197-1205.	0.2	40
134	Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival. <i>Gastroenterology</i> , 2018, 155, 967-969.	0.6	3
135	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2461-2467.	0.9	50
136	Comparison of Endoscopic Dysplasia Detection Techniques in Patients With Ulcerative Colitis: A Systematic Review and Network Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2518-2526.	0.9	46
137	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
138	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
139	Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 742-753.	3.7	40
140	Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2366-2376.	0.9	6
141	Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. <i>Current Drug Targets</i> , 2018, 19, 740-747.	1.0	3
142	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	3.6	1,294
143	Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 110-121.	8.2	272
144	Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 665-674.e5.	2.4	124

#	ARTICLE	IF	CITATIONS
145	Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 381-390.	1.9	34
146	Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 374-388.e4.	0.6	108
147	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017, 9, CD011572.	1.5	13
148	Predictors Of Treatment Failure After Radiofrequency Ablation For Intramucosal Adenocarcinoma in Barrett Esophagus. <i>American Journal of Surgical Pathology</i> , 2016, 40, 554-562.	2.1	16
149	How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 998-1009.	0.9	18
150	Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. <i>Cancer Prevention Research</i> , 2016, 9, 887-894.	0.7	133
151	Next-Generation Therapeutics for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2016, 18, 51.	1.1	19
152	Magnetic resonance elastography identifies fibrosis in adults with alpha ₁ -antitrypsin deficiency liver disease: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 287-299.	1.9	31
153	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. <i>BMJ, The</i> , 2016, 355, i6188.	3.0	66
154	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. <i>Journal of Hepatology</i> , 2016, 65, 1006-1016.	1.8	275
155	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-to-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257
156	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2424.	3.8	614
157	A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 262-271.	1.9	101
158	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	0.6	39
159	Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 8999.	1.4	26
160	Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 783-792.	1.9	141
161	Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1245-1253.	1.9	53
162	Assessment of mucosal healing in inflammatory bowel disease: review. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 246-255.	0.5	74

#	ARTICLE	IF	CITATIONS
163	Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. American Journal of Gastroenterology, 2015, 110, 1631-1632.	0.2	12
164	Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis. Pharmacotherapy, 2015, 35, 412-423.	1.2	13
165	Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 1266-1275.	1.9	71
166	Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 3366-3372.	1.3	21
167	Anti-Tumor Necrosis Factor Monotherapy Versus Combination Therapy with an Immunomodulator in IBD. Gastroenterology Clinics of North America, 2014, 43, 441-456.	1.0	20
168	Systematic review: monotherapy with antitumour necrosis factor agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	6.1	106
169	Risks of Serious Infection or Lymphoma With Anti-Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2014, 12, 1443-1451.	2.4	137
170	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2014, 43, 525-541.	1.0	39
171	Effects of dose reduction on gemcitabine-based neoadjuvant chemoradiotherapy for localized pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, e15262-e15262.	0.8	0
172	Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study. Gastrointestinal Endoscopy, 2013, 77, 534-541.	0.5	44
173	Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2927-2936.	0.9	25
174	Disseminated Sarcoidosis Presenting as Granulomatous Gastritis. Journal of Clinical Gastroenterology, 2012, 46, 367-374.	1.1	30
175	How May the Transition to Value-Based Payment Influence Gastroenterology: Threat or Opportunity?. Clinical Gastroenterology and Hepatology, 2012, 10, 609-611.	2.4	12